[{"arm_notes": "", "treatment_id": null, "treatment_name": "Intervention1: Covishield (SII-ChAdOx1 nCoV-19): Covishield will be administered as 2 dose schedule on Days 1 and 29 as 0.5 ml dose intramuscularly.Control Intervention1: Oxford/AZ-ChAdOx1 nCoV-19 vaccine: Oxford/AZ-ChAdOx1 nCoV-19 vaccine will be administered as 2 dose schedule on Days 1 and 29 as 0.5 ml dose intramuscularly.Control Intervention2: Placebo: Placebo will be administered as 2 dose schedule on Days 1 and 29 as 0.5 ml dose intramuscularly.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Intervention1: Covishield (SII-ChAdOx1 nCoV-19): Covishield will be administered as 2 dose schedule on Days 1 and 29 as 0.5 ml dose intramuscularly.Control Intervention1: Oxford/AZ-ChAdOx1 nCoV-19 vaccine: Oxford/AZ-ChAdOx1 nCoV-19 vaccine will be administered as 2 dose schedule on Days 1 and 29 as 0.5 ml dose intramuscularly.Control", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Control Intervention1: Oxford/AZ-ChAdOx1 nCoV-19 vaccine: Oxford/AZ-ChAdOx1 nCoV-19 vaccine will be administered as 2 dose schedule on Days 1 and 29 as 0.5 ml dose intramuscularly.Control Intervention2: Placebo: Placebo will be administered as 2 dose schedule on Days 1 and 29 as 0.5 ml dose intramuscularly.", "treatment_type": "Placebo", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}, {"arm_notes": "0,5ml;2;day1-29 (Covishield SII-ChAdOx1 nCoV-19)", "treatment_id": 161, "treatment_name": "Chadox1 ncov-19", "treatment_type": "Non replicating viral vector", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "0,5ml;2;day1-29 (Oxford/AZ-ChAdOx1 nCoV-19)", "treatment_id": 161, "treatment_name": "Chadox1 ncov-19", "treatment_type": "Non replicating viral vector", "pharmacological_treatment": "Vaccine"}]

[{"arm_notes": "", "treatment_id": null, "treatment_name": "N/A", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": null, "treatment_name": "Intervention1: Covishield (SII-ChAdOx1 nCoV-19): Covishield will be administered as 2 dose schedule on Days 1 and 29 as 0.5 ml dose intramuscularly.Control Intervention1: Oxford/AZ-ChAdOx1 nCoV-19 vaccine: Oxford/AZ-ChAdOx1 nCoV-19 vaccine will be administered as 2 dose schedule on Days 1 and 29 as 0.5 ml dose intramuscularly.Control Intervention2: Placebo: Placebo will be administered as 2 dose schedule on Days 1 and 29 as 0.5 ml dose intramuscularly.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Intervention1: Covishield (SII-ChAdOx1 nCoV-19): Covishield will be administered as 2 dose schedule on Days 1 and 29 as 0.5 ml dose intramuscularly.Control Intervention1: Oxford/AZ-ChAdOx1 nCoV-19 vaccine: Oxford/AZ-ChAdOx1 nCoV-19 vaccine will be administered as 2 dose schedule on Days 1 and 29 as 0.5 ml dose intramuscularly.Control", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Control Intervention1: Oxford/AZ-ChAdOx1 nCoV-19 vaccine: Oxford/AZ-ChAdOx1 nCoV-19 vaccine will be administered as 2 dose schedule on Days 1 and 29 as 0.5 ml dose intramuscularly.Control Intervention2: Placebo: Placebo will be administered as 2 dose schedule on Days 1 and 29 as 0.5 ml dose intramuscularly.", "treatment_type": "Placebo", "pharmacological_treatment": "TODO"}]